Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This study will investigate the safety and efficacy of TIL therapy in patients with
metastatic TNBC who have progressed on at least one and no more than three prior systemic
anticancer therapies.